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      Abstract  
2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203, NSC 703786) lysylamide belongs to a 
novel mechanistic class of antitumor agents.  It elicits activity against ovarian, breast, kidney and 
colorectal cancer models. In sensitive breast cancer cells, 5F203 activates aryl hydrocarbon 
receptor (AhR) signaling. Herein, we evaluate the role of AhR in 5F203 activity in two ovarian 
cancer cell lines: IGROV-1 (sensitive to 5F203), SKOV-3 (resistant to this agent). In addition, 
cancer cells have been isolated from ascites fluid of ovarian cancer patients; sensitivity to 5F203 
and concurrent AhR signal transduction has been examined in ascites-isolated ovarian cancer 
patients` cells.   
5F203 induced enhanced CYP1A1 expression, AhR translocation and ROS formation in IGROV-1 
cells and ascites-isolated ovarian cancer cells that were sensitive to 5F203.  In IGROV-1 cells 
5F203-induced ROS formation was accompanied by JNK, ERK and P38MAPK phosphorylation, 
DNA damage and cell cycle arrest prior to apoptosis. In contrast, 5F203 failed to induce CYP1A1 
expression, AhR translocation or oxidative stress in 5F203-resistant SKOV-3 cells, or in ovarian 
cancer ascites cells inherently resistant to this agent. 
We propose that AhR may represent a new molecular target in the treatment of ovarian tumors and 
5F203 may exemplify a potential novel treatment. Furthermore, putative biomarkers of 
sensitivity to this agent have been identified.  
 Introduction 
Ovarian malignancies, the second cause of gynaecological cancer death in developed countries  
possess poor prognoses. Detected at advanced stages of disease (III and IV), the standard of care is 
cytoreductive surgery followed by platin- and taxane-based chemotherapy. Intrinsic- or acquired 
resistance to cytotoxic drugs result in significant risk of recurrence;  therefore, the discovery of 
new molecular targets and more effective therapies remain vital (Romero and Bast, 2012). 
It has been proposed that high-grade advanced stage papillary serous ovarian adenocarcinoma 
ascites fluid is enriched for “metastasis initiating cells” which may represent a therapy-resistant 
population. Thus, ascites is considered a good model for disease study (Vathipadiekal et 
al., 2012).  
Antitumor benzothiazoles including, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203; 
NSC 703786; Fig. 1A), non-fluorinated parent compound DF203 (NSC 674495) and Phortress 
(NSC 710305), the lysyl amide prodrug of 5F203, are anticancer agents with activity in ovarian and 
breast cancer models in vitro and in vivo (Bradshaw et al., 2000; Fichtner et al., 2004). These 
compounds require metabolism by cytochrome P450 (CYP) enzymes (e.g. CYP1A1) for antitumor 
action. The aryl hydrocarbon receptor (AhR) is the main transcriptional regulator of CYP1A1 and 
we have previously demonstrated that DF203 and 5F203 induce activation of AhR signaling in 
sensitive breast cancer cells, causing nuclear translocation of AhR (Loaiza Perez et al., 2002; 
Bradshaw et al., 2008). Also, IGROV-1 human ovarian cancer cells, sensitive to 5F203 treatment, 
show induction of CYP1A1 expression by 5F203 and Phortress whereas SKOV-3 cells, resistant to 
these agents, express neither constitutive nor inducible CYP1A1 (Hose et al., 2003). Fine needle 
aspirates obtained from IGROV-1 human xenografts, treated ex vivo with 5F203 resulted in 
induction of CYP1A1 expression. This was not observed in 5F203-resistant tumors. It was 
proposed that induction of CYP1A1 mRNA in response to 5F203 treatment ex vivo may provide a 
possible biomarker for determination of drug-sensitive ovarian tumors in patients (Hose et al., 
2003). Compounds that activate AhR signaling and induce CYP expression frequently 
generate reactive oxygen species (ROS) in susceptible cells. Experimental and clinical 
evidence has emerged linking oxidative stress to pathologies including carcinogenesis 
(Ziech et al., 2011). However, oxidative stress is not always detrimental, and may, if 
induced in a selective manner, be of therapeutic benefit. Many chemotherapeutic agents 
induce oxidative stress integral to their antitumor mechanism (Tandon et al., 2005). High 
grade ovarian tumors generally present high ROS levels and respond better to treatment with 
antitumor agents that induce further ROS, such as paclitaxel (Mateescu et al., 2011). In addition, c-
JUN amino terminal kinase (JNK), ERK and P38MAPK sustained activation have key roles in 
cellular stress-induced apoptosis (Zuco et al., 2004). 
Herein, we demonstrate that 5F203 induced enhanced CYP1A1 expression and AhR nuclear 
translocation in IGROV-1 cells and ascites-isolated ovarian cancer cells that were sensitive to 
5F203. 5F203 possessed antiproliferative/pro-apoptotic activity evoking ROS formation, JNK, 
ERK and P38MAPK phosphorylation, DNA damage and cell cycle arrest prior to apoptosis. In 
contrast, 5F203 failed to induce CYP1A1 expression, AhR translocation or oxidative stress in 
5F203-resistant SKOV-3 cells, or in ovarian cancer ascites cells inherently resistant to this agent.  
Our studies demonstrate theranostic pharmacodynamic markers of 5F203 activity and provide 
additional insight into molecular targets of this novel anticancer agent, which may benefit ovarian 
cancer patients with limited therapeutic options. 
 
Materials and Methods 
Cell lines 
Human ovarian cancer cell lines IGROV-1 and SKOV-3 were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured with 5% CO2 in RPMI 1640 
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Invitrogen) and passaged 
weekly. Cells were resurrected at early passages from the nitrogen bank and discarded after 10 
passages to ensure minimal phenotypic drift. 
 
Primary cultures 
Informed consent was obtained from women who had undergone surgery at Ángel H. Roffo 
Oncology Institute. Peritoneal fluids were obtained at the time of initial cytoreductive surgery. 
Cancer cells in ascites fluid were identified and verified by pathologists within the pathology 
department at Ángel H. Roffo Oncology Institute.  
Fresh effusions drained from each patient were transferred to 50 ml tubes. Cells were prepared 
according to Shepherd et al., 2006. Tumor cell samples were used at low passage (<5), cultured with 
5% CO2 in MCDB/M199 supplemented with 10% FBS and passaged weekly. 
 
AhR Western blot  
Cells were seeded at 6 x 105 in T25 flasks 24 h before treatment with 1 µM 5F203 for 30 min 3 h, 6 
h; 0.1 % DMSO 6 h or 10 nM 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD) 1 h. Following 
treatment, cells were harvested, lysed and centrifuged using a commercial kit (NER-PER, Pierce, 
Rockford, IL, USA) to isolate cytosolic and nuclear fractions. Protein concentrations were 
determined using the Bradford assay. Fractions were analyzed by Western blot with rabbit 1o Ab 
against human AhR (sc-5579, Santa Cruz Biotechnology, CA, USA). Membranes were incubated 
with goat anti rabbit IgG-HRP 2o Ab (Santa Cruz, sc- 2004) and visualized using enhanced 
chemiluminescence. Equal protein loading was confirmed by reprobing membranes with mouse 
anti-actin Ab (Sigma, A5441).  
 
Confocal laser scanning microscopy 
Cells were seeded into sterile petri dishes containing a single sterile coverslip in 10 ml medium, 
and allowed to attach overnight (o/n). Medium containing 5F203 (1 μM) was introduced and 
cultures incubated at 37°C. After treatment, cells were fixed with 4% neutral buffered formalin and 
permeabilized with 0.1% Tween in PBS. Slides were blocked at 4°C for 1 h with 5% BSA in PBS 
and washed with PBS (3x) before incubation (o/n) with anti-AhR rabbit polyclonal Ab (sc-5579, 
Santa Cruz Biotechnology; 1:100 in PBS). Slides were washed 3x with PBS, before incubation with 
goat anti-mouse Alexa 488-conjugated 2o Ab (Sigma; 1:100, 3 h). Following further PBS washes 
(3x), slides were incubated with 1:5000 propidium iodide (2 mg/ml; Sigma). Cells (on coverslips) 
were mounted onto glass slides using fluoromount (BDH Laboratory Supplies, Poole, UK) and 
stored at 4°C in the dark. Specimens were examined using a Fluorescence Nikon C1 Confocal 
Microscope using a 40x PlanApo AN 0. 95 objective, images were processed and analyzed with 
Nikon C1-EZ package, version 2.20. 
 
Transient transfections 
Cells were plated in 24 well plates and after 24 h were transfected using lipofectamine 2000 
(Invitrogen) with 0.5 μg Renilla reniformis luciferase and 1.5 μg pTX.Dir plasmid (two XRE 
sequences extending from nucleotides -1026 to -999 relative to the transcription start site of the rat 
CYP1A1 inserted in a vector containing the herpex simplex virus thymidine kinase (TK) promoter 
and the luciferase reporter gene) (Nordeen et al., 1998) or pT81 (same reporter plasmid without the 
XRE sequence, used as a negative control) (Berghard et al., 1993). After 24 h, transfected cells 
were treated with 10 nM TCDD; 0.1 μM 5F203, 1 μM 5F203, 0.1 μM 5F203 plus 1 μM α-
naphthoflavone (α-NF) or 1 μM 5F203 plus 1 μM α-NF, as indicated. Control cells were 
transfected with pTX.Dir and treated with DMSO (0.1 %). After 18 h treatment, luciferase activity 
was measured by the Dual-Luciferase Assay System (Promega) following manufacturer´s 
instructions. Transfection efficiency was monitored by R. reniformis luciferase activity using the 
pRL-TK plasmid as an internal control.  
 
 
Measurement of intracellular reactive oxygen species  
Intracellular ROS were measured using the fluorescent dye 2´,7´-dichlorodihydrofluorescein 
diacetate (H2DCF-DA; Sigma). Cells were treated with 0.1% DMSO or 5F203. DCF fluorescence 
intensity (measured by flow cytometry or fluorometry) is proportional to the amount of intracellular 
ROS. In selected experiments, cells were treated with α-NF (1 μM), N-acetyl-cystein (NAC) (100 
mM) or Trolox (250 μM) for 30 min prior to 5F203 treatment. As a positive control 500 μM H2O2 
was used. 
 
4, 6-Diamidino-2-phenylindole (DAPI) staining  
Cells were seeded at 2.5 x 105 in 35 mm dishes o/n, then exposed to DMSO (0.1%) or 5F203 (1 
μM) for 24 h or 48 h. Floating cells were collected by cytocentrifugation. Once fixed, cells were 
stained with 0.4% DAPI and observed under a fluorescence microscope. Experiments were 
repeated ≥3x. Condensed and fragmented nuclei were considered apoptotic.  
 
Determination of pERK, pJNK and pp38 
Western blot analyses were performed using total lysates of cells treated with 5F203 (1 μM) for  1 
h, 3 h and  6 h using pERK, ERK and pJNK antibodies of Santa Cruz (sc-7383 and sc-135900, 
1:200, sc-6254, 1:500, respectively), JNK  antibody (Cell Signaling #9258, 1:1000), pp38 antibody 
(Cell Signaling #9211, 1:500) and p38 antibody (Cell Signaling #9217, 1:1000). . 
 
Determination of Caspase 3 and PARP  
Western blot analyses were performed using total lysates of cells treated with 5F203 (1 μM) for 30 
min, 1 h, 3 h, 6 h, 24 h and 48 h using caspase 3 antibody of Santa Cruz (sc-7841; 1:200) and 
poly(ADP-ribose) polymerase (PARP) Pharmingen, Becton Dickinson, Mountain View, CA, USA  
(556494; 1:500). 
 
Determination of p-p53 and p21  
Western blot analyses were performed as described by Chomczynski and Sacchi, 1987, on lysates 
of cells treated with 5F203 (1 μM) for 30 min, 1 h, 3 h, 6 h, 24 h and 48 h using antibodies to p-p53 
(Ser 392) Chemicon (Millipore, Billerica, MA, USA, AB4060; 1: 600) and p21 Cell Signaling 
Technology, Beverly, MA, USA (Cat #2946; 1: 500).  
 
Flow cytometry 
Exponentially growing IGROV-1 cells were exposed to 0.1% DMSO (control) or 5F203 (1 µM) for 
24 h, 48 h, or pre-incubated for 1 h with α-NF (1 µM) followed by 24 h or 48 h of 5F203 + α-NF (1 
μM). Exponentially growing SKOV-3 cells were exposed to 0.1% DMSO or 5F203 (1 µM) for 24 h 
or 48 h. Thereafter, cells were harvested, washed in PBS, and fixed in 70% ethanol. DNA was 
stained by incubating cells in PBS containing propidium iodide; fluorescence was measured and 
analyzed using Cyflogic software version 1.2.1. 
 
Determination of Cyclin D1  
Western blot analyses were performed using total lysates of cells treated with 5F203 (1 μM) for 30 
min, 1 h, 3 h, 6 h, 24 h and 48 h using anti-Cyclin D1 (Thermo Fisher Scientific, Kalamazoo, MI, 
USA,  cat # RB-9041, rabbit Ab, 1:10000). 
 
Evaluation of CYP1A1 expression 
Total RNA was isolated using Trizol Reagent (Chomczynski and Sacchi, 1987). RNA 
concentration was estimated by measuring the optical density at 260 nm and 2 μg RNA was reverse 
transcribed by using i-Script cDNA synthesis Kit.  
Real-Time PCR for CYP1A1 was performed in a 25 μl mixture containing cDNA (1μl), 0.20 mM 
dNTPs, specific primers (Sanada et al., 2009) were used at 0.25 μM, 3 mM MgCl2, 1 U Taq DNA 
polymerase and 1:30,000 SYBR Green Stain. Real-Time PCR reactions were performed in a C1000 
Thermal Cycler (Biorad) and the amplification program consisted of an initial denaturing step 
(94°C for 5 min), followed by 40 cycles (each of 94°C for 30 s, 60°C for 30 s and 72°C for 30 s). 
Sample quantification was normalized to endogenous GAPDH which was also quantified by Real-
Time PCR (Mc Kinney and Robbins, 1992), following the same protocol as that for CYP1A1. 
Fluorescence signal acquisition was carried out at the end of the elongation step. Each assay 
included a DNA minus control. All samples were run in duplicate and the experiment repeated 3x 
with independently isolated RNA. RNA expression changes were calculated using the 2−ΔΔCt 
method. 
 
 Statistical Analyses 
Statistical significance between 3 or more groups was calculated by one-way analysis of variance 
(ANOVA) followed by Tukey´s test. To compare 2 groups, the unpaired Student´s t test with 
Welch correction was used. Statistical analysis was performed using GraphPad InStat version 3.06 
for Windows 95, GraphPad software, San Diego, California, USA, www.graphpad.com. 
Designations for statistical significance are *p<0.05, **p<0.01 and ***p<0.001.  
 
Results 
 
5F203 induces AhR translocation and activation of CYP1A1-Related Promoter Sequences in 
5F203-sensitive ovarian cancer cells 
 
It has been established that 5F203 is a potent AhR ligand (Bazzi et al, 2009) able to induce nuclear 
translocation of AhR with subsequent binding to xenobiotic responsive elements (XRE sequences) 
and transcriptional activation of target genes including CYP1A1 and CYP1B1 in breast cancer cells 
sensitive to this agent (Loaiza-Perez et al., 2002). As 5F203 causes IGROV-1 cytotoxicity 
(Supplementary Fig. 1) and consistent with the hypothesis that 5F203 is an AhR agonist ligand 
(Bradshaw et al., 2008), we wished to determine whether 5F203 activates AhR signaling in 
IGROV-1 cells  with resulting AhR translocation from cytoplasm to nucleus.  
The effect of 5F203 (1 µM) on subcellular distribution of immunoreactive AhR protein was studied 
by Western blot. As demonstrated (Fig. 1B), in IGROV-1 cells treated with DMSO only, the 
cytoplasmic fraction contained relatively high levels of AhR protein compared with the nuclear 
fraction. In contrast, after treatment of cells with AhR agonists, 1 μM 5F203 or 10 nM TCDD 
(positive control), between 1 and 6 h, immunoreactive AhR protein could be detected in the nuclear 
fraction, indicating AhR translocation has taken place.  
To identify whether 5F203 caused AhR nuclear translocation in 5F203-insensitive ovarian 
carcinoma cells, the effect of 5F203 (1 µM) on subcellular distribution of immunoreactive AhR 
protein was assessed by Western blot in SKOV-3 cells. In DMSO-treated cells, AhR protein levels 
were high in cytoplasmic and nuclear fractions. After treatment with 1 μM 5F203 (0.5 – 6 h), AhR 
protein in SKOV-3 cytoplasm remained unchanged - AhR was already present in SKOV-3 nuclei, 
further translocation to the nuclear fraction was negligible. After treatment with TCDD, although 
cytoplasmic AhR was lost, there was no evidence of AhR gain in nuclear fractions (Fig. 1B). These 
results were confirmed by inmmunofluorescence of AhR (pictures obtained by confocal 
microscopy are shown in supplementary Fig. 2). It was then logical to investigate putative 
activation of CYP1A1-related promoter sequences in 5F203 sensitive ovarian cancer cells. 
CYP1A1 and CYP1B1 promoters are regulated by AhR, which forms a heterodimer with the AhR 
nuclear transporter (ARNT). Binding of the complete dimer to XRE promoter regions mediates 
transcription of AhR-responsive genes, including CYP1A1. IGROV-1 and SKOV-3 were 
transfected with XRE-luciferase reporter construct (pTX.Dir), as a control, the same reporter 
construct without XRE elements (pT81) was used. Cells were then treated with 0.1% DMSO, 0.1-1 
μM 5F203 or TCDD 10 nM. In IGROV-1 cells transfected with pTX.Dir, 5.5-fold induction of 
luciferase activity was observed when cells were treated with 1 μM 5F203 (Fig. 1C). No induction 
in luciferase activity was observed when SKOV-3 cells transfected with pTX.Dir were treated with 
5F203 (1 μM). Cells transfected with pT81 and treated with 1 μM 5F203 showed negligible 
luciferase activity induction (1.1-fold). These findings clearly demonstrate that 5F203 induces 
activation of promoter sequences known to respond to AhR-mediated signals. This is consistent 
with interaction of protein complexes induced by treatment with 5F203 through the XRE CYP1A1 
promoter sequence. 
In IGROV-1 cells pre-treated for 1 h with AhR antagonist α-NF (1 μM) followed by co-treatment 
(18 h) with 5F203 plus 1 μM α-NF, reduced induction (2.65-fold) of luciferase activity was 
observed. These results corroborate involvement of AhR in increased XRE-luciferase activity. 
 
5F203-induced ROS and γH2AX foci formation in sensitive cells is mediated by AhR 
 
Previous studies demonstrated CYP1A1 induction by 5F203, and 5F203 biotransformation to DNA 
reactive species (Wang and Guengerich, 2012). CYP activity contributes to increased intracellular 
ROS (Vibhuti et al., 2010). Oxidative stress is involved in various biological processes including 
proliferation and apoptosis. Therefore, we compared the effect of 5F203 on ROS production in 
benzothiazole-sensitive IGROV-1 cells and -insensitive SKOV-3 cells. To determine whether 
5F203 altered intracellular ROS levels, we treated cells with 5F203 ≤ 6 h and exposed them to 2,7-
DCF before evaluating ROS levels using flow cytometry. 5F203 increased ROS in IGROV-1 cells 
only. This effect, detectable following 1 h 1 μM 5F203 treatment was partially blocked by pre-
incubation of cells with α-NF (Fig. 2A). Also, pre-treatment with ROS inhibitors N-acetyl cysteine 
(NAC) and Trolox, partially decreased the effect of 5F203 in IGROV-1 cells (Fig. 2B). In contrast, 
5F203 strongly inhibited ROS production in SKOV-3 cells, despite detection of neither phenotypic 
changes nor AhR translocation. It is reported that ROS may cause activation of nuclear factor 
kappa B (NF-κB) (Morgan and Liu, 2011). As activation of this pathway induces NF-κB nuclear 
translocation, we performed immunostaining of NF-κB using a specific antibody in IGROV-1 and 
SKOV-3 cells before and after treatment with 5F203. 5F203 induced NF-κB translocation in 
IGROV-1 cells only, and this effect was prevented by pre-treatment of cells with 1 μM α-NF 
(Supplementary Fig.3). 
We then investigated whether 5F203 caused DNA damage. To determine DNA double strand 
breaks (DSB), γH2AX foci were measured in IGROV-1 and SKOV-3 cells following exposure to 
5F203 (1 μM, 2-4 h). DNA DSB formation precipitates serine 139 phosphorylation of histone 
H2AX, producing γH2AX at DSB sites (Rogakou et al., 2000). γH2AX foci appeared within nuclei 
of IGROV-1 cells only following treatment with 5F203 (1 µM; 2-4 h; Fig. 2C). Foci formation was 
partially blocked by pre-treatment of cells with α-NF, confirming that activation of AhR is needed 
for 5F203-induced DNA damage. In contrast, neither vehicle-treated cells nor SKOV-3 cells 
challenged with 5F203 displayed γH2AX foci within their nuclei at any time point examined.  
 
5F203 modulates expression and phosphorylation of stress MAPKs.    
Mitogen activated protein kinases (MAPK) can be modulated by many factors including 
cell lesions induced by DNA damage (Rogakou et al., 2000). We therefore investigated the 
effect of 5F203 on activation of these protein kinases in IGROV-1 cells. As observed in 
Figure 3A, 5F203 induced phosphorylation of JNK and P38 (2.26 and 8.16-fold 
respectively, supp. Fig. 4A), the stronger effect was attained after 6 h treatment in both 
cases.   Also, treatment with 5F203 increased P38α expression (2.44-fold – 10.62-fold; 1 
h – 6 h respectively, supp. Fig. 4A). Pre-treatment of cells with α-NF decreased 
phosphorylation of these kinases and P38α expression which confirmed that 5F203 affected 
expression and activation of these proteins through AhR activation. We also observed that 1 h 
exposure to 5F203 increased phosphorylation of ERK in IGROV-1 cells (1.44-fold; 
supplementary Figure 4A).  
The ability of 5F203 to induce apoptosis was evaluated. Exposure of IGROV-1 cells to 
5F203 (1 μM; 24 h) induced apoptotic body formation (Figure 3B). In contrast, SKOV-3 
cells, resistant to 5F203, did not show such features (Figure 3B). Also, pre-treatment of 
cells with α-NF partially blocked the pro-apoptotic effect of 5F203 in IGROV-1 cells. These 
data confirm that AhR is involved in 5F203-induced cell death. 
Trolox (a vitamin E derivative) and NAC are potent ROS scavengers often used as 
antioxidant agents. We pre-treated IGROV-1 cells with Trolox or NAC in order to 
investigate the effect of ROS depletion on 5F203-induced growth inhibition. Cells were 
exposed to 5F203 (1 μM, 24 h) after pre-treatement with Trolox (250 μM) or NAC (100 
mM) for 1 h. As observed in figure 3B both inhibitors partially reduced 5F203-induced 
apoptotic body formation. These data reveal the role of ROS in 5F203-induced apoptosis 
in sensitive IGROV-1 cells.   
 
5F203 causes altered cell cycle distribution and apoptosis in sensitive ovarian cancer cells 
As our results indicate that 5F203 induced DNA damage (Fig. 2B), we investigated perturbations in 
cell cycle. For this approach, IGROV-1 and SKOV-3 cells were exposed to 1 μM 5F203 or 0.1% 
DMSO for 24 h and 48 h and subsequently processed for cell cycle analyses. As illustrated (Fig. 
4A), 5F203 caused an increase in G1 phase IGROV-1 cells (44% control;  50% at 24 h and 59% at 
48 h), coinciding with  decreased G2/M phase cells (20% control to 13% at 24 h and 9% at 48 h). 
Accumulation of sub-G1 events was also detected from 5% (control) to 12% at 24 h and 20% at 48 
h. When cells were pre-incubated with α-NF sub-G1 events diminished indicating that AhR 
activation is necessary for 5F203-induced apoptosis. In contrast, SKOV-3 cell cycle was not 
perturbed following treatment with 5F203.The data demonstrate that 5F203-induced DNA damage 
may lead to accumulation of cells in G1 phase concomitant with growth inhibition. As IGROV-1 
cells are p53 wild type, their response to 5F203 is consistent with operation of a G1 checkpoint 
arrest to cell cycle progression after DNA damage.  
As G1 phase arrest was observed in 5F203-sensitive cells, we examined cyclin D1 levels after 
treatment. Results demonstrate that exposure of IGROV-1 cells to 5F203 reduced cyclin D1 protein 
levels by 50% and 75% after 24 h and 48 h respectively. In contrast, only a 35% decrease in cyclin 
D1 levels was observed in SKOV-3 cells after 48 h treatment with 5F203 (Fig. 4B). 
In order to study whether 5F203 treatment caused caspase 3 activation, PARP cleavage and p53 
phosphorylation in IGROV-1 cells as a result of its pro-apoptotic action, we carried out Western 
blot experiments upon separated proteins of whole cell lysates following treatment of cells with 1 
μM 5F203 between 3-48 h. We observed caspase 3 activation, PARP cleavage and 2.7- and 4-fold 
increased p53 phosphorylation between 24 h and 48 h respectively. A similar pattern of increased 
p21 protein levels was observed after treatment of IGROV-1 cells with 5F203 (Fig. 4C). In 
contrast, caspase activation, PARP cleavage and changes in pp53 and p21 protein levels were not 
detected in SKOV-3 cells treated with 5F203 (Fig.4C). 
 
Cytotoxicity of 5F203 in cells isolated from ovarian cancer  ascites is mediated by AhR   
 
Cancer cells, derived from ascites fluid produced by ovarian tumors from three patients were 
authenticated by pathologists. All tumors were high grade (G3), serous, papillary histological type. 
Cells were treated in culture with 5F203 for 5 days and cytotoxicity measured using MTS assays. 
Two cell strains were sensitive to 5F203 and one was resistant (Fig. 5A). In patient A, 1 µM and 10 
µM 5F203 decreased cell viability by 40% and 50% respectively (compared to control considered 
100%). This decrease in cell viability diminished to 20% and 30% respectively when cells were 
pre-treated with 1 µM α-NF followed by incubation with 5F 203/α-NF. We observed similar results 
in cells derived from patient B (data not shown). These results indicate that AhR mediates the 
effect of 5F203 in these papillary tumors sensitive to 5F203 (Fig. 5B). AhR nuclear translocation 
was then investigated in these ovarian cells. As demonstrated in Fig. 5C, in cells treated with 
DMSO, high levels of AhR protein was detected in cytosol and nucleus. After treatment with 10 
μM 5F203 or 10 nM TCDD for 1 h, immunofluorescent AhR protein increased in the nucleus and 
decreased in the cytosol. In contrast, constitutive nuclear AhR localization was detected in 
cells of patient C - resistant to 5F203. CYP1A1 mRNA levels were measured by Real 
Time PCR in cells from patients A, B (sensitive to 5F203) and C (resistance to 5F203) 
following exposure to 5F203 (1 µM; 24 h). In cells from patients A and B, we observed 
23.88 ± 4.07- and 2.4± 0.28-fold induction of CYP1A1 expression, respectively (Fig. 6A), 
which was partially reduced by α-NF. In contrast, reduction of CYP1A1 expression was 
observed after treatment of patient C cells with 5F203. Finally ROS levels were evaluated 
after treatment of patient ascites cells with 5F203. Increased ROS levels were detected 
only in cells sensitive to 5F203, ROS were not induced in the 5F203-insensitive ascites 
cells of patient C (Fig. 6B). 
 
Discussion 
In this paper we show for the first time that 5F203 activates AhR signaling in cultured and patient 
ovarian carcinoma cells sensitive to this agent, demonstrating that 5F203 cytotoxicity is AhR 
dependent. In sensitive IGROV-1 cells, 5F203 a known AhR ligand (Bazzi et al., 2009) triggers 
AhR translocation from cytosol to nucleus, activating CYP1A1-related promoter sequences driving 
transcription of AhR responsive genes as reported by XRE-luciferase.  
It was recognized several years ago that certain ovarian cancer cell lines were exquisitely sensitive 
to antitumor benzothiazoles (Bradshaw et al., 1998). 5F203 potency and selectivity against ovarian 
cell lines within the NCI panel have been demonstrated (Bradshaw et al., 1998; Hutchinson et al., 
2001): IGROV-1, OVCAR4 and OVCAR5 displayed GI50 values <100 nM in contrast, GI50 values 
>10 µM were observed in OVCAR8 and SKOV-3 cells. Subsequently induction of CYP1A1 by 
5F203 in sensitive cancer cells only inferred significant correlation between sensitivity and 
CYP1A1 induction (Hose et al., 2003). In vivo, antitumor activity of 5F203 prodrug Phortress was 
demonstrated against IGROV-1 tumors. Moreover, CYP1A1 expression was detected in IGROV-1 
tumors of mice receiving Phortress treatment. No CYP1A1 protein was detected in insensitive 
breast tumor tissue following treatment of mice with Phortress (Leong et al., 2004). 
Differential sensitivity to 5F203 may be a consequence of differential regulation by AhR of CYP1A1 
expression in different cell types. In resistant cells we observed constitutive nuclear localization of 
AhR.  In resistant cells AhR may be associated with co‐repressors (Hestermann and Brown, 2003); 
lack of AhR degradation  (by ubiquitination) or recycling may  lead to  inappropriate AhR  function 
(Ma and Baldwin, 2000). Also,  different AhR  nuclear  localization  sequences  (Ikuta  et  al.  1998; 
Ikuta et al., 2000) or polymorphisms may cause inappropriate receptor function (Rowlands et al., 
2010). Additionally, mutations in the CYP1A1 promoter in insensitive cells may lead to decreased 
CYP1A1 activation (Zheng et al., 2010). 
Considering the clinical potential of 5F203, its mechanism of action was further investigated. 
5F203 induced ROS formation in sensitive cells (Fig. 2). In IGROV-1 cells 5F203 evoked DNA 
damage detected as γH2AX foci (2-4 h), increased pp53 levels and P21 expression, decreased 
cyclin D1 expression, caused G1 cell cycle arrest and apoptosis. In contrast, SKOV-3 cells showed 
decreased levels of pp53 after treatment with 5F203, the reason for this effect is unclear but it may 
contribute to cellular resistance to 5F 203 (Fig. 4).   
5F203-induced growth inhibition and apoptosis in IGROV-1 cells may in part be a consequence of 
elevated ROS (Fig. 2A) and caspase 3 activation (Fig. 4C) resulting in oxidative DNA damage and 
cell death. Oxidative stress may activate caspases and is implicated in a number of cellular 
processes including apoptosis. Many chemotherapeutic agents are known to induce cytotoxicity by 
ROS-mediated mechanisms e.g. doxorubicin (Lin et al., 2007) and AhR ligand Aminoflavone 
(McLean et al., 2006). 
It was demonstrated that ROS may trigger apoptosis signaling mediated by p53 in IGROV-1 cells 
(Righetti et al., 1999; Casinelli et al., 2001). IGROV-1 cells possess wild type p53 and show 
sensitivity to 5F203. However, 5F203 activity is independent of p53 exemplified by i) potent 
activity of 5F203 in MDA-MB-468 p53 mutant cells  (Bradshaw et al. 1998)  ii) IGROV-1 variant 
populations demonstrating acquired resistance to cisplatin retain sensitivity to 5F203 (Bradshaw et 
al, unpublished results). Cisplatin resistance is associated with p53 mutations in IGROV-1 cells 
(Perego et al., 1996). In IGROV-1 cells, p53 may be attempting (failed) repair rather that mediating 
apoptosis. 
Our results show that antioxidant agents such as NAC and Trolox decrease ROS formation and 
protect IGROV-1 cells from apoptosis induced by 5F203(Fig. 3B). Previous work has demonstrated 
that stress signaling pathways are also activated by cisplatin and retinoids in IGROV-1 and 
cisplatin-resistant IGROV-1 cells, furthermore activation of JNK and P38 by these agents is 
stronger in cisplatin-resistant IGROV-1 cells. Reflecting that integral to antitumor activity, 
5F203 induces ROS in sensitive IGROV-1 cells and that IGROV-1 cells resistant to 
cisplatin retain sensitivity to 5F203, we propose that 5F203 could be a putative treatment 
for ovarian tumors.  
 
MAPK p38α acts as an oxidative stress sensor; ROS-induced activation of p38 promotes apoptosis 
and prevents further oncogenic/carcinogenic ROS formation (Mateescu et al., 2011) Also micro-
RNAs (miRNA) expression can be altered by different stress conditions and are well known stress 
response regulators. It has been described that two members of the miR-200 family, miR-141 and 
miR-200a, inhibit p38α and have an essential role in the redox response. In animal models, 
accumulation of miRNAs mimics p38α deficiency and promote malignancy. Human ovarian 
adenocarcinomas demonstrating high oxidative stress show high expression of miR-200a and low 
basal levels of p38α. Chemotherapy drugs that induce ROS also induce p38α in these tumors, 
leading to apoptosis.  It was proposed that in ovarian tumors high levels of miR-200s and low 
levels of p38α could be predictive markers of good clinical response to chemotherapy (Mateescu et 
al., 2011). Our results are consistent with these observations, IGROV-1 cells have low levels of 
basal p38α and treatment with 5F203 induced p38α expression and pp38 (Fig. 3A), which may lead 
to apoptosis. In contrast, SKOV-3 cells show high basal levels of p38α and treatment with 5F203 
did not modulate p38α expression or activation (Fig. 3A). We hypothesize that this may contribute 
to the lack of apoptosis induction in SKOV-3 cells.  
Finally, compatible with results from ovarian cancer cell lines, we identified putative in vitro 
surrogate markers of sensitivity to 5F203 in a small sample of patient tumors. Clear 
distinction was demonstrated between ovarian cancer patient tumor cells that were 
sensitive to 5F203 and those which were inherently 5F203-resistant.  Only in ascites-
isolated patient tumor cells sensitive to 5F203 was i) cytosolic AhR translocation to cell 
nuclei, ii) CYP1A1 mRNA induction, iii) increased ROS levels observed (Fig. 5 and 6) in 
response to ex vivo treatment. Such pharmacodynamic endpoints are readily obtained 
from bioassays that could be adopted clinically to detect candidate 5F203-responsive 
patients. In this way, unresponsive patients would be spared unnecessary treatment. 
Sensitivity to 5F203, and AhR activation should be examined in a larger sample of ovarian 
carcinoma patient tumors of different histological types in future studies. However, the fact that 
cells isolated from patients with high grade ovarian tumors were sensitive to 5F203 shows that this 
agent may offer alternative treatment for patients with advanced disease. Intraperitoneal (i.p.) 
chemotherapy is currently used in treatment of ovarian tumors and both 5F203 and its prodrug 
Phortress have demonstrated antitumor efficacy administered either intravenously or i.p. (Bradshaw 
et al, 2002; Hose et al., 2003).  
In summary, we have demonstrated AhR-dependent cytotoxicity of 5F203 in ovarian carcinoma 
cells, we conclude that AhR may represent a new molecular target in the treatment of ovarian 
cancer and that 5F203 may offer a potential novel treatment for this disease.  
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